We propose to develop and analyze a set of mathematical models aimed at understanding the humoral immune response and the generation of immune memory. In vivo, immune responses occur primarily in secondary lymphoid organs. Germinal center formation and somatic hypermutation of antibodies being critical aspects. The regulation and control of these local events are currently under intense experimental scrutiny and involve an interesting set of quantitative problems related to B and T cell population dynamics, control of somatic mutation, the selection events driving affinity maturation, the generation of immune memory, and the role of the spatial structure and local germinal center environment in these processes. Theoretical and quantitative analysis of these issues may be able to generate new ideas and insights. Our models will address the events occurring during B cell responses in splenic foci and germinal centers, concentrating on antigen retention by follicular dendritic cells, somatic mutation and the role of the spatial structure of germinal centers in selecting high affinity cells. We also propose to develop physical chemical theories for affinity based selection, and will examine the role of somatic mutation in the immune response to evolving pathogens. Specific health related issues include improving our understanding of the generation of immune memory and hence our ability to make more effective vaccines, and hate role of somatic mutation in providing protection against rapidly mutating pathogens. Further, progress in developing comprehensive quantitative models of immune system events will improve our understanding of the operation of the immune system as a whole in fighting disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI028433-08
Application #
2667707
Study Section
Special Emphasis Panel (ZRG7-SSS-4 (02))
Project Start
1990-07-01
Project End
2001-02-28
Budget Start
1998-03-01
Budget End
1999-02-28
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Los Alamos National Lab
Department
Type
Organized Research Units
DUNS #
City
Los Alamos
State
NM
Country
United States
Zip Code
87545
Ke, Ruian; Conway, Jessica M; Margolis, David M et al. (2018) Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. JCI Insight 3:
Aunins, Thomas R; Marsh, Katherine A; Subramanya, Gitanjali et al. (2018) Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms. J Virol 92:
Vaidya, Naveen K; Ribeiro, Ruy M; Liu, Pinghuang et al. (2018) Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. Front Microbiol 9:1326
Chang, Christina C; Naranbhai, Vivek; Stern, Jared et al. (2018) Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. AIDS 32:2119-2128
Quintela, Barbara de M; Conway, Jessica M; Hyman, James M et al. (2018) A New Age-Structured Multiscale Model of the Hepatitis C Virus Life-Cycle During Infection and Therapy With Direct-Acting Antiviral Agents. Front Microbiol 9:601
Perelson, Alan S; Ribeiro, Ruy M (2018) Introduction to modeling viral infections and immunity. Immunol Rev 285:5-8
Cao, Youfang; Lei, Xue; Ribeiro, Ruy M et al. (2018) Probabilistic control of HIV latency and transactivation by the Tat gene circuit. Proc Natl Acad Sci U S A 115:12453-12458
Goyal, Ashish; Romero-Severson, Ethan Obie (2018) Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil. PLoS One 13:e0203831
Ishida, Yuji; Chung, Tje Lin; Imamura, Michio et al. (2018) Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology 68:473-484
Canini, Laetitia; Lemenuel-Diot, Annabelle; Brennan, Barbara J et al. (2018) A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor. Antivir Ther 23:353-361

Showing the most recent 10 out of 253 publications